If you have been reading about storage stability and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-07. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
He was also accused of having returned to the Ayacucho Capitulation an agreement with humiliating conditions for Peruvians, which would not feel like a victory."Doctor Olañeta has told me that he believes it is not only difficult but impossible to reunite the high provinces to Buenos Aires: that there is an irreconcilable enmity: that they remain independent or attached to Peru; because the vote of men of judgment is about to belong to the Peru, in which case they want the capital in Cuzco, or closer to them. May this news serve as the government, which is corroborated by many others, so that you can tell me based on these data what to do or proceed in these businesses. My position can give me the case of giving some march to the opinion of those towns and you will tell me what is best for the public cause." The considerations of Sucre's decree would be contradictory and weak to camouflage anti-Peruvian sentiment. On the one hand, he would say that "it is not up to the liberation army to intervene in the businesses of these towns," and yet he convened a political assembly under the auspices of the President of Colombia (Bolívar). He would also say that Argentina, heir to the viceregal rights over Upper Peru, "lacks a General Government" and that "there is therefore no one to deal with", but he does not mention that Peru also had rights, as well as that its government was established and running.
In 1977, the institute was officially affiliated to the Ministry of Scientific Research By June 1978 the TBRI's laboratories and out-patients clinic were inaugurated. The attached hospital was completed in December 1981, and the official opening was in 1983 according to Presidential Decree No. 58. The institute which started with 12 research departments and 120 bed hospital became this institution encompassing 20 research departments covering a wide spectrum of academic and clinical specialties divided into six divisions (Clinical Medical Division, clinical Surgical Division, Clinical Laboratory Research Division, Immunology &Therapeutic Evaluation Division, Biochemistry &Medicinal Chemistry Division, Medical Malacology & Environmental Research Division). The 20 departments are: Gastroenterology, Hepatology, Nephrology, Public Health, Radiology., Anaesthesia, Intensive care, Surgery, Urology, Clinical Chemistry, Electron Microscopy, Hematology, Microbiology, Pathology, Immunology, Parasitology, Pharmacology, Biochemistry, Medicinal Chemistry, Environmental Research and Medical Malacology departments.
=== Binding of SSRIs to SERT protein === The molecular basis for SSRIs function, including their binding mode and molecular mechanism of 5-HT re-uptake inhibition in SERT, is not fully understood and is a matter of debate. Such information is very important for the understanding of essential aspects of the drugs action, ranging from selectivity profile to therapeutic efficacy and the development of new and improved drugs that target the human SERT. The three-dimensional (3D) structure of SERT is not known and has been the main obstacle for elucidation of the structural mechanism of the human SERT. Update: X-ray crystallography data is available as of 2017 it seems (https://www.rcsb.org/structure/6AWO)... Comparative molecular modeling have been used in research to create structural models of human SERT in complex with its ligand but has not given good results because of low phylogenetic and functional similarity between human SERT and available template proteins. However the 3D structure of some bacterial homologous transporters like the leucine transporter (LeuT) is known. The human SERT, NET and DAT are all members of the neurotransmitter:sodium symporter (NSS) protein family. SERT contains approximately 630 amino acids that are predicted to form 12 transmembrane alpha-helixes (TMs) which are connected with intra- and extracellular loops (ILs and ELs).
In Food and Allied Workers Union and Another v The Cold Chain, an important case in South African labour law, the Labour Court held that there was nothing absurd in permitting a senior managerial employee to participate in the activities of a trade union, provided that the employee complies with his contractual obligations. In this case, the employee was offered a managerial position as an alternative to retrenchment, on condition that he no longer participated in the activities of the trade union. When he refused, he was retrenched. The court did not hesitate to find the dismissal to be automatically unfair.
Sources: en.wikipedia.org
=== The syringe tide environmental disaster === The syringe tide environmental disaster of 1987–1988 raised awareness about medical waste as medical syringes washed ashore in Connecticut, New Jersey, and New York. The syringes endangered marine species and posed a threat to humans who visited the beach. The crises spurred scientists and lawmakers to create mechanisms, policies, and laws so that health care providers would process their bio-waste in an environmentally friendly way.
July also saw the addition of two more names to the list of deaths, as Paulson's death became the 22nd linked to the drug, and a 17-year-old member of a high school drill team died at Parkland Memorial Hospital eleven days after being found unconscious on the morning her group was to take its yearbook photo.
== Comparable technology == Liquid vaccines generally do not survive freezing, with the notable example of the OPV. Accidental freezing may occur with improper use of ice packs. A freeze indicator can be used to indicate whether something has ever been put under freezing temperatures, with one made by the manufacturer of VVM already prequalified by the WHO. Regular time temperature indicators such as the VVMs do not reflect temperature spikes well. A color-changing peak time temperature indicator (PTTI) can be used in addition to the VVM. The PTTI have a similar form factor but only change color after a set temperature (and does so quickly). A "VVM+" has been released that combines both. An electronic temperature data logger can detect all the above changes along with precise times for when irregularities in temperature have happened. They are more expensive, however.
==== Moisture content differences ==== The chemical potential is explained here since it is the true driving force for the transport of water in both liquid and vapour phases in wood. The Gibbs free energy per mole of substance is usually expressed as the chemical potential of that substance. The chemical potential of water in unsaturated air or wood below the fibre saturation point influences the drying of wood. Equilibrium will occur at the equilibrium moisture content (as defined earlier) of wood when the chemical potential of water in the wood becomes equal to that in the surrounding air. The chemical potential of sorbed water is a function of wood moisture content. Therefore, a gradient of wood moisture content (between surface and centre), or more specifically of water activity, is accompanied by a gradient of chemical potential under isothermal conditions. Moisture will redistribute itself throughout the wood until its chemical potential is uniform throughout, resulting in a zero potential gradient at equilibrium. The flux of moisture attempting to achieve the equilibrium state is assumed to be proportional to the difference in its chemical potential, and inversely proportional to the path length over which the potential difference acts. The gradient in chemical potential is related to the moisture content gradient as explained in above equations. The diffusion model using the moisture content gradient as a driving force was applied successfully by Wu (1989) and Doe et al. (1994).
On 29 September P.W. Botha added a third objective to Operation Moduler: the destruction of all FAPLA units east of Cuito Cuanavale. The reasons for this shift in objectives once FAPLA had abandoned its offensive were not apparent to everybody in the South African government. Pik Botha and his senior colleagues in the foreign ministry cautioned against a major offensive north of the Lomba, citing potential diplomatic repercussions. But confidence in the SADF had been buoyed by its effective defence of the Lomba, and members of the South African general staff successfully agitated for a renewed offensive towards Cuito Cuanavale. It is unclear whether they interpreted their new objective as veiled permission to seize Cuito Cuanavale itself, although the option was discussed. Per Botha's new directive, the SADF commenced Operation Hooper with the goal of encircling the retreating Angolan brigades and preparing for operations further east of the Cuito River. The decision to commence Hooper towards the end of the 1987 calendar year created problems for the SADF, since a number of white conscripts involved in the Lomba River engagements were nearing the end of their national service. This led to a delay of several weeks while the existing troops were gradually withdrawn from Angola and replaced with a new intake. The SADF had dispatched a second mechanised battalion, 4 South African Infantry, to Angola, as well as a squadron of Olifant Mk1A tanks and a battery of G5 and G6 howitzers.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.